Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106509 | 0.85 | MET (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL371742 | 0.85 | MET (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL21185552 | 0.82 | PDGFRB (0.57) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL29576571 | 0.82 | PDGFRB (0.57) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL198505 | 0.82 | PDGFRB (0.68) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL21185496 | 0.81 | PDGFRA (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL29576979 | 0.81 | PDGFRB (0.58) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL4400367 | 0.80 | PDGFRB (0.72) | PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL21176864 | 0.79 | PDGFRB (0.68) | PDGFRBPDGFRAFGFR2EGFRKDR | |
| SCHEMBL21753513 | 0.79 | PDGFRB (0.59) | PDGFRBPDGFRAFGFR2EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | CSF1R, CSF3R, FLT3 | PDGFRB 136/4885PDGFRA 161/4885FGFR2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.